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Transgenic mice were generated by injecting the entire
rat angiotensinogen gene into the germline ofNMRI mice.
The resulting transgenic animals were characterized with
respect to hemodynamics, parameters of the renin
angiotension system, and expression of the transgene. The
transgenic line TGM(rAOGEN)123 developed hyper-
tension with a mean arterial blood pressure of 158 mmBHg
in males and 132 mmHg in females. In contrast, the
transgenic line TGM(rAOGEN)92 was not hypertensive.
Rat angiotensinogen was detectable only in plasma of
animals of line 123. Total plasma angiotensinogen and
plasma angiotensin H concentrations were about three
times as high as those of negative control mice. In
TGM(rAOGEN)123 the transgene was highly expressed
in liver and brain. Transcripts were also detected in
heart, kidney and testis. In TGM(rAOGEN)92 the brain
was the main expressing organ. In situ hybridization
revealed an mRNA distribution in the brain of
TGM(rAOGEN)123 similar to the one in rat. In
TGM(rAOGEN)92 the expression pattern in the brain
was aberrant. These data indicate that overexpression
of the angiotensinogen gene in liver and brain leads to
the development of hypertension in transgenic mice. The
TGM(rAOGEN)123 constitutes a high angiotensin II type
of hypertension and may provide a new experimental
animal model to study the kinetics and function of the
renin angiotensin system.
Key words: angiotensinogen/brain/hypertension/liver/trans-
genic mice
Introduction
The renin angiotensin system (RAS) is the most important
regulator of blood pressure and body electrolyte homeostasis.
Angiotensinogen (AOGEN), the only high molecular weight
protein precursor of angiotensins, is cleaved by renin to
angiotensin I (ANG I), which is subsequently converted by
the action of converting enzyme to the potent vasoconstrictor
octapeptide hormone angiotensin II (ANG II) (for reviews
see Peach, 1977; Dzau and Pratt, 1986; Lindpaintner and
Ganten, 1991). The main source of plasma AOGEN is the
liver (Campbell et al., 1984), where its synthesis and release
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into the circulation is regulated in response to a number of
different stimuli such as steroid hormones (Chang and
Perlman, 1987; Feldmer et al., 1991), cytokines (Brasier
et al., 1990; Ron et al., 1990a) and ANG II (Klett et al.,
1988a,b). In the past decade the existence of local tissue RAS
has been established. Gene expression of components of the
RAS, including AOGEN has been demonstrated in a large
number of extrahepatic tissues, among them the brain, heart
and kidney (Ohkubo et al., 1986; Deschepper et al., 1986;
Campbell and Habener, 1987; Dzau et al., 1987; Hellmann
et al., 1988; Stornetta et al., 1988). The transcription of the
AOGEN gene in these tissues seems to be regulated in a
cell type specific manner (Campbell and Habener, 1986).
In situ hybridization of rat brain revealed a predominant ex-
pression of the AOGEN gene within nuclei related to cardio-
vascular control (Lynch et al., 1986; Bunnemann et al.,
1990). However, the functional relevance of locally
generated ANG II in the development of hypertension is not
yet fully understood.
An increasing number of studies has successfully employed
transgenic animal models to elucidate the participation of
candidate genes in the development of pathophysiological
changes within the organism (Hsiao et al., 1990; Hammer
et al., 1990; Ryan et al., 1990; Weiher et al., 1990). The
generation of hypertensive transgenic rats harbouring the
mouse renin gene (Mullins et al., 1990) for the first time
provided evidence for a local paracrine mechanism in the
development of hypertension. These rats have extremely high
blood pressure with low circulating renin and ANG II levels.
To investigate whether the overexpression of the AOGEN
gene can also lead to the development of high blood pressure,
we generated transgenic mice carrying the rat AOGEN gene.
The mouse is particularly suited for these experiments
because it is known to have low circulating AOGEN
concentrations and because the mouse renin is capable of
cleaving rat AOGEN. The use of a heterologous gene (mouse
versus rat) allows the differential analysis of the endogenous
verus the transgene. We obtained different lines of transgenic
mice and report here on the characteristics of these animals
with respect to plasma parameters, hemodynamics and the
expression pattern of the transgene. We demonstrate that the
transgenic mouse line TGM(rAOGEN)123 expresses high
levels of the transgene in liver and brain, has elevated plasma
AOGEN and ANG II concentrations, and develops
hypertension.
Results
Generation of transgenic mice
The genomic rat AOGEN clone pRagl5U (Tanaka et al.,
1984) (Figure 1), including 1.6 kb of 5' flanking sequences,
was microinjected into fertilized eggs of NMRI mice as a
14.2 kb linear EcoRI-Hindlll fragment. Three foster
mothers carried 16 mice to term, four of which carried the
transgene as analysed by Southern blotting ofDNA obtained
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Fig. 1. Southern blot analysis of transgenic mice. Schematic map of the 14.2 kb EcoRI (E)-HindIII (H) fragment of pRagl5U used for
microinjection of NMRI mice. Hatched boxes, designated I-V, represent the five exons of the rat AOGEN gene, which are interrupted by four
introns (thick solid lines). Thin lines represent 1.6 kb of 5' and 0.9 kb of 3' flanking sequences, respectively. BamHI (B) and PvuII (P) restriction
sites, which are relevant for Southern analysis, are indicated. Genomic mouse DNA was digested with PvuII and hybridized to a 712 bp BamHI
fragment of the rat AOGEN cDNA. The appearance of two hybridization signals is indicative of the presence of the transgene. Numbers above the
lanes indicate the transgenic lines that were established from the particular founder animal. The left lane (neg) contained DNA of a transgene
negative litter-mate.
from tail biopsies (Figure 1). Three of these founder animals
transmitted the transgene to their progeny and the transgenic
lines, TGM(rAOGEN)92, 102 and 123 were established.
RNase protection analyses of total liver RNA of animals
of these three lines showed that the transgene was highly
expressed in TGM(rAOGEN)102 and 123 (Figure 5 and data
not shown). We chose TGM(rAOGEN)123 for further
investigation, because the transgene segregated in a
Mendelian manner as opposed to TGM(rAOGEN) 102, in
which there seemed to be multiple insertion sites obviously
on different chromosomes. This resulted in a complex
genetics in the F2 generation. Expression of the transgene
in the liver of animals of line 92 was very weak (Figure 5).
All experiments reported here were carried out with
heterozygous animals of transgenic lines 92 and 123.
Transgenic mice have elevated AOGEN and ANG 11
levels
To test whether the expression of the rat AOGEN gene in
the liver of transgenic mice results in elevated circulating
protein concentrations, we measured several plasma
parameters of the RAS. Using the ELISA technique with
the rat AOGEN specific monoclonal antibody Al-F6 we
detected high levels of rat AOGEN in the plasma
of TGM(rAOGEN)123 with no significant difference
between females (15.1 + 2.55,tg/ml) and males
(16.3 2.14 itg/ml) (Figure 2A). However, as in negative
control animals, no specific reaction of the antibody with
plasma proteins of TGM(rAOGEN)92 could be detected
(Figure 2A). This indicates that the concentration of rat
AOGEN in the plasma of TGM(rAOGEN)92 is below the
limit of detection of the ELISA and that the antibody does
not cross-react with the mouse AOGEN.
The total rat and mouse plasma AOGEN concentration
was measured by indirect RIA via the generation of ANG
I. Animals of TGM(rAOGEN)123 showed >2-fold
higher total substrate concentrations than those of
TGM(rAOGEN)92 or transgene negative litter-mates (Figure
2B). Again there was no difference between male and female
animals. Since the data for rat and total AOGEN
concentrations were obtained with different (direct and
indirect) methods, it is not possible to calculate the exact
contribution of rat AOGEN to the concentration of total
AOGEN.
Plasma ANG II concentrations were determined by direct
radioimmunoassay (RIA) and found to be about three times
higher in TGM(rAOGEN) 123 than in normal mice (Figure
822
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Fig. 2. AOGEN concentration in plasma of transgenic mice. (A)
Plasma rat AOGEN concentrations were determined by ELISA using
the monoclonal antibody Al-F6 (see Materials and methods). (B) Total
AOGEN concentrations were measured by indirect RIA via the
generation of ANG I. Plasma aliquots were incubated for 3 h with a
kidney homogenate of NMRI mice. Columns represent the
mean ± SEM of values obtained from measurements of plasma
samples of six or more male (M) or female (F) animals, each carried
out in two parallel determinations. n.d., not detectable, asterisks
indicate significant differences to the respective negative control as
stated in Materials and methods.
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Fig. 3. ANG II concentration in plasma of transgenic mice. Plasma
ANG II concentrations were determined by direct RIA. Calculation
and presentation of data is as in Figure 2.
3). Interestingly, male but not female animals of
TGM(rAOGEN)92 also had elevated plasma ANG II
concentrations (Figure 3).
Transgenic mice develop high blood pressure
Since animals of TGM(rAOGEN)123 had increased
circulating substrate and ANG II level, we measured the
mean arterial blood pressure (MAP) to determine whether
the increased effector peptide concentrations have
hemodynamic effects. The data in Figure 4 were obtained
by measuring the MAP in five or more different animals
of each group. Clearly, animals of TGM(rAOGEN) 123 have
significantly elevated blood pressure compared with normal
mice. Male transgenics develop higher pressure
(159 8 mmHg) than female animals (131 4 5 mmHg)
as compared with 107 + 3 mmHg for both male and female
negative litter-mates. Animals of TGM(rAOGEN)92 had
normal blood pressure.
The transgene is expressed in different tissues
The expression of the transgene as well as of the endogenous
mouse AOGEN gene was analysed by RNase protection
assay. This method discriminates between mouse and rat
mRNAs. The RNA preparations were simultaneously
hybridized to mouse and rat AOGEN antisense RNA. Initial
experiments demonstrated the species specificity of the
cRNA probes. No specific signals were obtained when the
mouse probe was hybridized to rat RNA (Figure 5, lane rL)
or vice versa (Figure 5, right panel).
The expression of the endogenous gene and the transgene
was analysed in liver, brain, kidney, heart and testis of
animals of both transgenic lines and of negative litter-mates
(Figure 5). InTGM(rAOGEN) 123 we detected rat AOGEN
mRNA in all of the above organs. Expression was highest
in liver and brain and detectable in kidney, heart and testis
[Figure 5, panel TGM(rAOGEN)123]. When compared with
the endogenous gene, transgene expression seemed to be
higher in the brain and lower in the other organs with the
exception of the liver [Figure 5, compare rAOGEN and
mAOGEN signals in TGM(rAOGEN)123 panel].
The expression pattern of the transgene in animals of
TGM(rAOGEN)92 was aberrant. Messenger RNA levels in
the liver are at the limit of detection, when we use 10 ,ug
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Fig. 4. Mean arterial blood pressure in transgenic mice. Control
animals were either negative litter-mates or age-matched normal NMRI
rmice. Columns represent the mean SEM of values obtained from
five or more animals. For abbreviations see legend to Figure 2. The
cross (+) indicates a significant difference between male and female
animals of line 123.
of total liver RNA for hybridization. However, in the brain
we detected considerable amounts of the mRNA, and weak
signals were present in kidney, heart and testis [Figure 5,
panel TGM(rAOGEN)92].
The RNase protection assay thus demonstrated that the
transgene is expressed in a number of different organs. In
order to study whether the expression occurs in a regional
and cell type specific manner in the brain, we performed
in situ hybridization on coronal sections of brain tissue of
transgene positive animals of lines 123 and 92 as well as
on negative control animals. In line 123, the transgene was
expressed in specific areas of the brain (Figure 6A and B).
The overall pattern was similar to the expression of the
endogenous AOGEN gene in the rat (Bunnemann et al.,
1990). We detected high mRNA levels in the preoptic area
(not shown) and in certain nuclei of the hypothalamus, e.g.
in the paraventricular hypothalamic nucleus (Figure 6A,
PHN), the suprachiasmatic nucleus (Figure 6A, SC), the
supraoptic nucleus (Figure 6A, SON) and the arcuate nucleus
(not shown). An expression pattern identical to the rat was
found also in the locus ceruleus of the pons (not shown),
in the Purkinje cell layer of the cerebellar cortex (Figure
6B, PL) and in the nucleus of the solitary tract (Figure 6B,
NTS) and the inferior olive (Figure 6B, 10) of the medulla
oblongata. There were, however, some differences as
compared with the rat. The expression in some nuclei of
the thalamus was higher in line 123 animals than in the rat
(Figure 6A, paraventricular thalamic nucleus, PTN). The
substantia nigra also showed high mRNA expression in
transgenic animals whereas in the rat this area contains only
moderate signals (not shown).
The expression pattern in the brain of animals of line 92
was very much different and comparable with the rat only
in pons and medulla (Figure 6D). In the other parts of the
brain, the very weak expression was restricted to the
suprachiasmatic nucleus (Figure 6C, SC) and the rostral
thalamus (not shown).
All signals observed were specific for rat AOGEN, since
no hybridization was detected with the rat AOGEN probe
in transgene negative mice or with a sense RNA probe in
positive animals (data not shown).
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Fig. 5. Expression of transgene and endogenous AOGEN gene in various organs of transgenic mice and normal NMRI controls. Total RNA of liver
(L, 10 Ag), brain (B, 20 Ag), kidney (K, 100 ,ug), testis (T, 100 Ag) and heart (H, 80 jig) of animals of both transgenic lines or of negative control
mice were hybridized overnight to a 200 bp mouse (M) and a 350 bp rat (R) AOGEN specific cRNA probe. Protected fragments of 150 bp
(mAOGEN) and 290 bp (rAOGEN) are indicative for the presence of rat and mouse AOGEN mRNA, respectively. Total rat liver RNA (10 jg, lane
rL) and tRNA (80 jig, lane tR) hybridized to both probes served as controls for specificity of the signals. The marker was Sau3A digested end
labelled pUC19 DNA, relevant sizes are indicated on the left. Two different exposures of the same gel were used to visualize weak signals.
Discussion
The generation of transgenic animals for the investigation
of human genetic diseases has gained increasing interest in
recent years (Connelly et al., 1989; Hanahan, 1989).
Transgenic animals have found entry also in cardiovascular
and hypertension research (Mullins et al., 1989, 1990;
Ohkubo et al., 1990; Steinhelper et al., 1990; Field, 1991).
The hypertensive transgenic rats TGR(mREN2)27, carrying
the mouse REN 2 gene (Mullins et al., 1990), were the first
monogenic hypertension model and provide direct evidence
that not only the classical circulating RAS but also local
paracrine tissue RAS can lead to the development of
hypertension.
Our rationale for introducing the rat AOGEN gene
expressed from its own promoter into the genome of the
mouse was two-fold. First, mouse renin is capable of
cleaving the rat AOGEN (Oliver and Gross, 1966). With
an additional AOGEN gene, we would increase the
circulating AOGEN concentration in the mouse, which was
reported to be relatively low (Poulsen and Jacobsen, 1986).
Since plasma substrate concentrations are the rate limiting
factor for ANG II formation (Reid et al., 1978), these
animals could provide a model to study RAS kinetics in vivo.
Second, using the natural promoter, we wanted to assure
a correct tissue specific expression of the transgene, thereby
providing a basis for a detailed analysis of cell specific gene
expression. Studies with the mouse AOGEN gene (Clouston
et al., 1989) and the closely related ail-antitrypsin gene
(Shen et al., 1989) indicated that sequences sufficient for
a correct expression of the AOGEN gene in transgenic
animals reside within 1-2 kb upstream of the start of
transcription. Such sequences should therefore be included
in the 1.6 kb of 5' flanking sequences present in our trans-
gene. In addition, we (Feldmer et al., 1991) and others (Ron
et al., 1990a,b) have shown that promoter elements
necessary for glucocorticoid, estrogen and cytokine induc-
tion are located within the first 700 bp of the start of
transcription.
In TGM(rAOGEN)123 the transgene is expressed in liver
and brain as well as in other tissues. In testis and kidney
there seems to be a dissociation between the expression of
the rat and the endogenous mouse AOGEN genes, the latter
being predominantly expressed. In testis, this might reflect
species specific differences in the level of expression, since
in Sprague- Dawley rats, the mRNA concentration in testis
is very low compared with other organs (Hellmann et al.,
1988). This is in contrast to the situation in some mouse
strains (Clouston et al., 1989). Differences between
promoter elements mediating testis specific expression of the
rat and the mouse genes might be responsible for this
phenomenon. Whether the low expression of the transgene
in the kidney is due to the lack of kidney specific cis-acting
elements on the transgene promoter or whether it is caused
by other regulatory mechanisms remains to be investigated.
The lack of tissue specific expression in TGM(rAOGEN)92
is likely to be due to integration artifacts (Palmiter and
Brinster, 1986). We can exclude a disruption of the trans-
gene, especially loss of promoter sequences, from Southern
analyses using promoter specific probes (data not shown).
Position-dependent expression has also been reported for
mouse AOGEN minigene constructs in transgenic mice
(Clouston et al., 1989) and might be attributed to transcrip-
tional interference from nearby promoters (Proudfoot, 1986).
The data reported here strongly support the hypothesis that
overexpression of AOGEN in a correct tissue specific
manner can lead to hypertension. Transgene expression in
the liver of TGM(rAOGEN) 123 resulted in increased total
plasma AOGEN and ANG II concentrations. The high rat
AOGEN mRNA content of the brain was localized by in
situ hybridization to areas and nuclei which are similar to
the endogenous mRNA distribution in the rat (Bunnemann
et al., 1990). Some of these nuclei are important centres for
cardiovascular control and all components of the RAS,
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Fig. 6. Localization of rat AOGEN mRNA in the brain of transgenic mice. Serial coronal sections (7 zm) of brains of mice of line 123 (A and B)
and line 92 (C and D) were hybridized to a rat AOGEN specific cRNA. Original autoradiographic signals were converted with an image analyser
which allows for a semi-quantitative analysis. Signal intensities increase from light yellow to red, the latter indicating areas of highest mRNA
concentrations. Sections of the rostral diencephalon (A and C) and the medulla oblongata (B and D) are shown to demonstrate the different
expression patterns between the lines and to indicate important areas of expression: paraventricular hypothalamic nucleus (PHN), suprachiasmatic
nucleus (SC), supraoptic nucleus (SON), paraventricular thalamic nucleus (PTN), Purkinje cell layer of the cerebellar cortex (PL), inferior olive (10),
nucleus of the solitary tract (NTS) and nucleus of the spinal tract of the trigeminal nerve (STN).
including AOGEN (Imboden et al., 1987), ANG II immuno-
reactivity (Lind et al., 1985) and ANG II receptors
(Mendelsohn et al., 1984) have been identified within these
nuclei. Animals of TGM(rAOGEN) 123 are hypertensive.
In contrast, TGM(rAOGEN)92, which, apart from elevated
plasma ANG II concentrations in males, did not show any
of the characteristic parameters found in
TGM(rAOGEN)123, were normotensive. The source of
ANG II in line 92 males is unclear at present, since the trans-
gene is only very weakly expressed in the liver and plasma
AOGEN concentrations are similar to negative control mice.
Plasma ANG II acts directly on vascular smooth muscle cells
to increase vascular tone and, in addition, leads to water
retention in the kidney by stimulation of aldosterone release
from the adrenal gland. Both of these actions increase the
blood pressure. Similarly, an overexpression of AOGEN in
the brain is likely to result in increased central ANG II
concentrations. This leads to an increase in sympathetic
nervous system activity via stimulation of noradrenalin
release. In addition, modulating regulatory mechanisms in
the periphery mediated by central release of humoral factors
might be changed by high ANG H concentrations in the
brain. Thus, an increased central ANG II concentration can
also lead to hypertension. The exact mechanisms underlying
a high ANG II mediated hypertension are not known, but
the transgenic mice of TGM(rAOGEN)123 provide the
opportunity to study these mechanisms and to gain
information about the kinetics of the RAS in vivo under
conditions of pharmacological intervention or further
stimulation of the system. These studies will also help to
elucidate the contribution of local tissue RAS to the develop-
ment of hypertension. The circulating RAS is not the sole
determinant of hypertension as suggested by the males of
line 92 which are normotensive despite plasma ANG II levels
similar to those of line 123 animals. Indirect evidence for
the involvement of local tissue RAS is also provided by
experiments of Ohkubo et al. (1990), who have generated
transgenic mice with a rat AOGEN gene fused to the mouse
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metallothionein I (mMT-I) promoter. Although the fusion
gene was highly expressed in the liver and the total plasma
concentrations ofAOGEN and ANG II were similar to the
values found in our hypertensive line, these mice were not
hypertensive. The mMT-I promoter is predominantly active
in the liver but also in the brain (Durham and Palmiter,
1981). This indicates that overexpression ofAOGEN in the
liver accompanied by an ectopic brain expression does not
lead to hypertension. Rather, a correct cell type specific
expression in the brain seems to be a prerequisite for the
hypertensive phenotype. Only those transgenic mice develop
this phenotype, which show correct brain expression.
Preliminary data with a third transgenic line,
TGM(rAOGEN)102, show that it is similar to line 123 with
respect to plasma parameters and tissue distribution of trans-
gene expression. Preliminary measurements on a limited
number of animals revealed an elevated blood pressure with
values comparable with line 123 (data not shown). The
establishment of this second hypertensive transgenic line
strongly supports the conclusions drawn from the data of
TGM(rAOGEN) 123.
Whether brain expression is necessary and sufficient for
the development of hypertension in the transgenic animals
of TGM(rAOGEN)123 or whether increased circulating
ANG II concentrations are also required awaits further
investigations. The RAS in other organs like the adrenal
gland can also be regarded as a major contributing factor
in hypertension. Evidence for this is provided by the
transgenic rats TGR(mREN2)27 which show highest
expression of the transgene in the adrenal gland and have
extremely high blood pressure despite a normal or even
suppressed plasma -RAS (Mullins et al., 1990). New
methodologies like tissue specific inhibition of transgene
expression in the renin overexpressing rats of
TGR(mREN2)27 and the AOGEN overexpressing mice of
TGM(rAOGEN)123 will help to clarify the role of tissue
RAS versus plasma RAS in the development of hypertension.
Materials and methods
Generation of transgenic mice
The plasmid pRaglS U, containing the 14.2 kb EcoRI-HindIII fragment
from the original 14.5 kb genomic rat AOGEN clone (Tanaka et al., 1984)
inserted into pUC19, was used to generate transgenic mice. This 14.2 kb
fragment was purified from vector sequences on a 0.8% agarose gel,
precipitated, redissolved in 10 mM Tris-HCI (pH 7.4)/0.2 mM EDTA
and filtered through 0.22 Mm sterile filter tips to remove inpurities. The
DNA (1 Ag/ln) was injected into fertilized oocytes of NMRI mice.
Southern blotting
Ten Mg of DNA obtained from tail biopsies of 3-4 week old mice were
digested with PvuII, separated on a 0.8% agarose gel and processed for
Southern hybridization by vacuum blotting onto Nylon Ny 13N membranes
(Schleicher and Schull). The probe used was a 712 bp BamHI fragment
of the rat AOGEN cDNA clone pRagl6 (Ohkubo et al., 1983). It was
radiolabelled with [a-32P]dCTP using the random prime method (Feinberg
and Vogelstein, 1983). Hybridization was carried out overnight at 65°C
and the membrane was exposed to X-ray film with an intensifying screen
at -800C.
Parameters of the RAS
Determination of rat AOGEN concentration in plasma was done by ELISA
as described (U.Hilgenfeldt, S.Schwind, T.Muley and I.Rubin, submitted),
using the monoclonal antibody A1-F6 directed against human AOGEN
(Rubin et al., 1988). Total plasma AOGEN concentration was determined
by indirect RIA via the generation of ANG I as described by Schelling et at.
(1980) with slight modifications. Plasma was incubated for a period of 3 h
with a 1:10 diluted kidney extract of NMRI mice which served as a source
of renin. Three hours were found to be sufficient to cleave quantitatively
both rat and mouse AOGEN. Plasma ANG II concentration was measured
by RIA essentially as described (Hermann et al., 1988).
Blood pressure measurements
Blood pressure measurements were performed by inserting a PE 10 catheter
into the femoral artery of the animals under pentobarbital anesthesia (Jacob
et al., 1991). After the operation (15-25 h) mean arterial blood pressure
was recorded on the conscious animals using a Stratham P23 D3 pressure
transducer connected to a Gould 2400 recorder. Pressure and heart rate
were recorded continously over a period of 15 min. Animals were sacrificed
thereafter and organs and blood were taken and processed for further
experiments.
RNA analysis
A 290 bp PvuII-BamHI fragment of pRagl6 was cloned into the BamHI
and SmaI restriction sites of the transcription vector pGEM 4 (Promega
Biotech). The resulting plasmid pRagO.3G4 was linearized with EcoRl and
then used for cRNA synthesis utilizing T7 RNA polymerase according to
the method of Melton et al. (1984).
The mouse AOGEN probe pMagO.15G4z which allowed for cRNA
synthesis with T7 RNA polymerase after linearizing with EcoRI was
constructed in the following way. A 6.3 kb BamHI fragment from the
genomic mouse AOGEN clone mAO (R.Metzger, unpublished) was
subcloned into Bluescript SK II (Stratagene) and subsequently digested with
EcoRI and BglII. The resulting 158 bp fragment was isolated and cloned
into the EcoRI and BamHI sites of pGEM4z (Promega Biotech) to yield
the plasmid pMagO.15G4z.
RNase protection assays were performed essentially as described by
Mullins et al. (1990). Briefly, total RNA was extracted from different tissues
using the LiCl/urea method (Auffray and Rougeon, 1980). Hybridization
was carried out overnight with 2 x 105 c.p.m. each of freshly labelled
antisense probes at 65 'C. RNase resistant hybrids were separated on a 5%
sequencing gel, which was then exposed to X-ray film at -80°C.
In situ hybridization
In situ hybridization on mouse brain was performned as previously described
(Bunnemann et al., 1990), using the plasmid pRagO.3G4 and [a-35S]UTP
to synthesize the cRNA probe. Radioactive signals were converted with
an image analyser (SAS Brovision, Milan, Italy).
Statistical analyses
Statistical analysis of data was performed with Student's t test or Anova
test. Differences were considered significant at P < 0.05 indicated by an
asterisk (*). Two asterisks indicate a value of P < 0.01.
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